DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer - PubMed (original) (raw)
. 2007 Feb 22;356(8):800-8.
doi: 10.1056/NEJMoa065411.
Affiliations
- PMID: 17314339
- DOI: 10.1056/NEJMoa065411
Free article
DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer
Zhong Zheng et al. N Engl J Med. 2007.
Free article
Abstract
Background: RRM1, the regulatory subunit of ribonucleotide reductase, is involved in carcinogenesis, tumor progression, and the response of non-small-cell lung cancer to treatment.
Methods: We developed an automated quantitative determination of the RRM1 protein in routinely processed histologic specimens. In these specimens, we measured the expression of RRM1 and two other proteins that are relevant to non-small-cell lung cancer: the excision repair cross-complementation group 1 (ERCC1) protein and the phosphatase and tensin homologue (PTEN). We compared the results with the clinical outcomes in 187 patients with early-stage non-small-cell lung cancer who had received only surgical treatment.
Results: RRM1 expression correlated with the expression of ERCC1 (P<0.001) but not with the expression of PTEN (P=0.37). The median disease-free survival exceeded 120 months in the group of patients with tumors that had high expression of RRM1 and was 54.5 months in the group with low expression of RRM1 (hazard ratio for disease progression or death in the high-expression group, 0.46; P=0.004). The overall survival was more than 120 months for patients with tumors with high expression of RRM1 and 60.2 months for those with low expression of RRM1 (hazard ratio for death, 0.61; P=0.02). Among these 187 patients, the survival advantage was limited to the 30% of patients with tumors that had a high expression of both RRM1 and ERCC1.
Conclusions: RRM1 and ERCC1 are determinants of survival after surgical treatment of early-stage, non-small-cell lung cancer.
Copyright 2007 Massachusetts Medical Society.
Comment in
- DNA repair and survival in lung cancer--the two faces of Janus.
Gazdar AF. Gazdar AF. N Engl J Med. 2007 Feb 22;356(8):771-3. doi: 10.1056/NEJMp068308. N Engl J Med. 2007. PMID: 17314336 No abstract available. - ERCC1 and non-small-cell lung cancer.
Niedernhofer LJ, Bhagwat N, Wood RD. Niedernhofer LJ, et al. N Engl J Med. 2007 Jun 14;356(24):2538-40; author reply 2540-1. doi: 10.1056/NEJMc070742. N Engl J Med. 2007. PMID: 17568038 No abstract available. - ERCC1 and non-small-cell lung cancer.
Panasci L, Cohen V. Panasci L, et al. N Engl J Med. 2007 Jun 14;356(24):2540; author reply 2540-1. N Engl J Med. 2007. PMID: 17575589 No abstract available. - ERCC1 and non-small-cell lung cancer.
Zhou SF. Zhou SF. N Engl J Med. 2007 Jun 14;356(24):2540; author reply 2540-1. N Engl J Med. 2007. PMID: 17575590 No abstract available. - Should oncologists measure the mRNA and protein expression levels of ERCC1 and RRM1 in non-small-cell lung cancer?
Heist RS, Liu G, Zhou W. Heist RS, et al. Nat Clin Pract Oncol. 2007 Oct;4(10):564-5. doi: 10.1038/ncponc0909. Epub 2007 Jul 31. Nat Clin Pract Oncol. 2007. PMID: 17667918 No abstract available.
Similar articles
- Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy.
Zhao H, Zhang H, Du Y, Gu X. Zhao H, et al. Tumour Biol. 2014 Dec;35(12):12679-88. doi: 10.1007/s13277-014-2592-7. Epub 2014 Sep 17. Tumour Biol. 2014. PMID: 25227663 - Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.
Simon GR, Schell MJ, Begum M, Kim J, Chiappori A, Haura E, Antonia S, Bepler G. Simon GR, et al. Cancer. 2012 May 1;118(9):2525-31. doi: 10.1002/cncr.26522. Epub 2011 Oct 25. Cancer. 2012. PMID: 22028294 Free PMC article. Clinical Trial. - ERCC1 and RRM1: ready for prime time?
Besse B, Olaussen KA, Soria JC. Besse B, et al. J Clin Oncol. 2013 Mar 10;31(8):1050-60. doi: 10.1200/JCO.2012.43.0900. Epub 2013 Feb 11. J Clin Oncol. 2013. PMID: 23401439 Review. - [ERCC1 and RRM1 genes in lung cancer].
Carvalho L, Silva A, Andrade C, Barroso C, Farinha C, Fernandes JC, Landeiro R. Carvalho L, et al. Rev Port Pneumol. 2009 Jul-Aug;15(4):683-96. doi: 10.1016/s0873-2159(15)30164-1. Rev Port Pneumol. 2009. PMID: 19552012 Review. Portuguese.
Cited by
- Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers.
Gray JE, Altiok S, Alexandrow MG, Walsh FW, Chen J, Schell MJ, Tai DF, Bepler G. Gray JE, et al. Cancer. 2013 Mar 1;119(5):1023-32. doi: 10.1002/cncr.27836. Epub 2012 Oct 12. Cancer. 2013. PMID: 23065656 Free PMC article. Clinical Trial. - Still no Rest for the Reductases: Ribonucleotide Reductase (RNR) Structure and Function: An Update.
Long MJC, Ly P, Aye Y. Long MJC, et al. Subcell Biochem. 2022;99:155-197. doi: 10.1007/978-3-031-00793-4_5. Subcell Biochem. 2022. PMID: 36151376 Review. - Progress in personalizing chemotherapy for bladder cancer.
Chang JS, Lara PN Jr, Pan CX. Chang JS, et al. Adv Urol. 2012;2012:364919. doi: 10.1155/2012/364919. Epub 2012 Feb 13. Adv Urol. 2012. PMID: 22400017 Free PMC article. - WEE1 kinase polymorphism as a predictive biomarker for efficacy of platinum-gemcitabine doublet chemotherapy in advanced non-small cell lung cancer patients.
Liu D, Wu C, Jiao Y, Hou L, Lu D, Zheng H, Chen C, Qian J, Fei K, Su B. Liu D, et al. Sci Rep. 2015 Jun 9;5:11114. doi: 10.1038/srep11114. Sci Rep. 2015. PMID: 26057002 Free PMC article. - Individualized Chemotherapy in Advanced NSCLC Patients Based on mRNA Levels of BRCA1 and RRM1.
Ren SX, Li AW, Zhou SW, Zhang L, Wang YS, Li B, Chen XX, Zhang J, Xu JF, Zhou CC. Ren SX, et al. Chin J Cancer Res. 2012 Sep;24(3):226-31. doi: 10.1007/s11670-012-0226-4. Chin J Cancer Res. 2012. PMID: 23359225 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials